Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pretax income is the income that a company earns before paying income taxes. Universal Ibogaine's pretax income for the
three
months ended in Apr. 2025 was $-0.05 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Apr. 2025 was $-1.06 Mil.
Universal Ibogaine's pretax margin was -9.38%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Universal Ibogaine Pre-Tax Income Related Terms
Universal Ibogaine Pre-Tax Income Historical Data
* Premium members only.
The historical data trend for Universal Ibogaine's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IBOGF vs LABT, CALC, LNAI: Pre-Tax Income Comparison
For the Biotechnology subindustry, Universal Ibogaine's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Universal Ibogaine Pre-Tax Income vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Universal Ibogaine's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Universal Ibogaine's Pre-Tax Income falls into.
Pre-Tax Income for the trailing twelve months (TTM) ended in Apr. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.06 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Universal Ibogaine (IBOGF) has a Pre-Tax Income of $-1.06 Mil as of Apr. 2025. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on Universal Ibogaine and its competitors.
Is Universal Ibogaine's Pre-Tax Income too high?
Universal Ibogaine's current Pre-Tax Income is $-1.06 Mil.
How does Universal Ibogaine's Pre-Tax Income compare to LABT and CALC?
Universal Ibogaine's Pre-Tax Income of $-1.06 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pre-Tax Income for a Biotechnology company?
A good Pre-Tax Income depends on the Biotechnology industry context. However, Pre-Tax Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pre-Tax Income mean?
A high Pre-Tax Income can signal that a stock is expensive relative to its fundamentals. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on Universal Ibogaine and its competitors. Universal Ibogaine's current Pre-Tax Income is $-1.06 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Universal Ibogaine stock overvalued right now?
Universal Ibogaine (IBOGF) has a current Pre-Tax Income of $-1.06 Mil. The current Pre-Tax Income is $-1.06 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pre-Tax Income calculated?
Pre-Tax Income is calculated from a company's financial statements. For Universal Ibogaine (IBOGF), the current Pre-Tax Income is $-1.06 Mil as of Apr. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Universal Ibogaine Inc is in the initial stages of implementing and financing its business plan, which is to develop a network of addiction treatment clinics and to undertake a planned clinical trial for research in Canada into the use of ibogaine, a natural plant-based substance, for addiction treatment. Its mission is to redefine the addiction recovery experience, providing those living with addiction the best possible recovery.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IBOGF has been successfully added to your 
